(973) 755-0387
Download PDF

Marina G. McGuire


Marina McGuire focuses her practice on handling all aspects of complex and high-stakes products liability and environmental and toxic tort litigation. Her practice is predominantly concentrated on the defense of large companies, including pharmaceutical and medical device manufacturers, in both federal and state court.

With a curated track record of success, Ms. McGuire handles matters ranging from individual actions to large-scale mass torts and other forms of MDL. Her experience specifically includes pharmaceutical, medical device and environmental matters.

Ms. McGuire heavily involves herself in all stages of litigation in coordination with in-house and co-counsel, when applicable, to develop effective legal strategies through the entire life of a case. This includes discovery, motion practice, depositions, expert work and preparing for trial. In mass tort matters, she brings the capability of leading jury and bench trials but also regularly utilizes the full spectrum of traditional and alternative dispute resolution methods, including assisting with mediations and arbitrations or seeking settlements beneficial to her clients.

In addition, Ms. McGuire conducts complex compliance investigations involving governmental regulations and employment issues impacting pharmaceutical companies.

Prior to entering private practice, Ms. McGuire served as a judicial law clerk to the Hon. Bruce A. Gaeta in the Superior Court of New Jersey, Bergen Vicinage. In addition, she was temporarily assigned as a judicial law clerk to the Hon. Charles J. Walsh in the same venue.

Bar Admissions
• New Jersey
• New York

Court Admissions
• U.S. District Court for the District of New Jersey

  • American Bar Association
  • Essex County Bar Association
  • National Association of Women Lawyers

  • New Jersey Super Lawyers Rising Star, Thomson Reuters, 2011-2018

  • Retain Resolution Counsel in Mass Torts as Part of an Effective Defense,” New Jersey Law Journal, July 2021
  • “An Ethical Roadmap for Developing and Refining High-End Technology Competence,” Celesq, February 2020
  • “Increased FDA Regulatory Action: The Current Landscape and Its Impact on Drug and Medical Device Litigation,” Pharmaceutical Law Update, March 2011
  • “Chapter 25 – Privilege in a Global Product Economy, Product Liability Litigation: Current Law Strategies and Best Practices,” Practicing Law Institute Treatise, 2nd, October 2009
  • “ Risk Assessment in Toxic Exposure Cases — Part I,” Law 360, September 2009
  • “Risk Assessment in Toxic Exposure Cases – Part II,” Law 360, September 2009
  • J.D., New York Law School (2003)
    • cum laude
  • B.S., University of Scranton (2000)